4//SEC Filing
CADENCE PHARMACEUTICALS INC 4
Accession 0000904454-14-000325
CIK 0001333248operating
Filed
Mar 20, 8:00 PM ET
Accepted
Mar 21, 6:59 PM ET
Size
28.8 KB
Accession
0000904454-14-000325
Insider Transaction Report
Form 4
BLAIR JAMES C
Director10% Owner
Transactions
- Disposition to Issuer
Common Stock
2014-03-19$14.00/sh−7,313,241$102,385,374→ 0 total(indirect: By Domain Partners VI, L.P.) - Disposition to Issuer
Common Stock
2014-03-19$14.00/sh−27,500$385,000→ 0 total(indirect: By LLC) - Disposition to Issuer
Stock Option (Right to Buy)
2014-03-19$7.65/sh−12,500$95,625→ 0 totalExercise: $6.35Exp: 2018-06-18→ Common Stock (12,500 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2014-03-19$6.84/sh−12,500$85,500→ 0 totalExercise: $7.16Exp: 2020-06-16→ Common Stock (12,500 underlying) - Disposition to Issuer
Common Stock
2014-03-19$14.00/sh−2,972,678$41,617,492→ 0 total(indirect: By Domain Partners VII, L.P.) - Disposition to Issuer
Stock Option (Right to Buy)
2014-03-19$11.02/sh−17,500$192,850→ 0 totalExercise: $2.98Exp: 2022-06-13→ Common Stock (17,500 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2014-03-19$6.79/sh−25,000$169,750→ 0 totalExercise: $7.21Exp: 2023-06-12→ Common Stock (25,000 underlying) - Disposition to Issuer
Common Stock
2014-03-19$14.00/sh−78,369$1,097,166→ 0 total(indirect: By DP VI Associates, L.P.) - Disposition to Issuer
Common Stock
2014-03-19$14.00/sh−50,743$710,402→ 0 total(indirect: By DP VII Associates, L.P.) - Disposition to Issuer
Stock Option (Right to Buy)
2014-03-19$1.70/sh−12,500$21,250→ 0 totalExercise: $12.30Exp: 2017-06-28→ Common Stock (12,500 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2014-03-19$4.63/sh−12,500$57,875→ 0 totalExercise: $9.37Exp: 2019-06-24→ Common Stock (12,500 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2014-03-19$4.75/sh−12,500$59,375→ 0 totalExercise: $9.25Exp: 2021-06-15→ Common Stock (12,500 underlying)
Footnotes (5)
- [F1]In connection with the acquisition of the Issuer by Mallinckrodt plc ("Parent") on March 19, 2014 (the "Merger"), and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Madison Merger Sub, Inc. ("Merger Sub") dated February 10, 2014, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $14.00 per Share.
- [F2]The Reporting Person is a Managing Member of One Palmer Square Associates VII, L.P., which is the sole general partner of Domain Partners VII, L.P. and DP VII Associates, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities beneficially owned by each such entity. The Reporting Person disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
- [F3]The Reporting Person is a Managing Member of One Palmer Square Associates VI, LLC, which is the sole general partner of Domain Partners VI, L.P. and DP VI Associates, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities beneficially owned by each such entity. The Reporting Person disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
- [F4]The Reporting Person is a Managing Member of Domain Associates, LLC. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities beneficially owned by such entity. The Reporting Person disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
- [F5]In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $14.00 over the exercise price per share of such option.
Documents
Issuer
CADENCE PHARMACEUTICALS INC
CIK 0001333248
Entity typeoperating
Related Parties
1- filerCIK 0001333248
Filing Metadata
- Form type
- 4
- Filed
- Mar 20, 8:00 PM ET
- Accepted
- Mar 21, 6:59 PM ET
- Size
- 28.8 KB